{
  "patient_id": "MBC_001",
  "subtype": "Luminal",
  "biomarker_summary": {
    "ER": "positive",
    "PgR": "positive",
    "HER2": "negative",
    "PIK3CA": "mutant",
    "BRCA1": "wild_type",
    "BRCA2": "wild_type",
    "PALB2": "wild_type",
    "MSI": "stable",
    "TMB": 3.2
  },
  "treatment_history_summary": "1 prior line(s), last: CDK4/6 inhibitor + aromatase inhibitor",
  "recommendations": [
    {
      "treatment": "Alpelisib + Fulvestrant",
      "evidence_level": "I",
      "recommendation_strength": "Moderate",
      "node_path": "Metastatic Breast Cancer Treatment Decision (ESMO 2021/24) -> Initial Biopsy, Biomarker & Staging Assessment (updated) -> Breast Cancer Subtype Classification -> Luminal Breast Cancer (ER+/HER2\u00e2\u20ac\u2018) -> Additional Biomarker Testing for Luminal BC (updated) -> Second\u00e2\u20ac\u2018line After CDK4/6 Progression (enhanced) -> PIK3CA\u00e2\u20ac\u2018mutant & HbA1c suitable",
      "rationale": "Patient has Luminal metastatic breast cancer. Recommended after progression on 1 prior line(s).",
      "keywords": [
        "selective estrogen receptor degrader",
        "alpelisib",
        "systemic therapy",
        "PIK3CA inhibitor",
        "PI3K inhibitor",
        "metastatic breast cancer",
        "fulvestrant",
        "SERD",
        "combination therapy"
      ]
    },
    {
      "treatment": "Everolimus + Exemestane",
      "evidence_level": "I",
      "recommendation_strength": "Moderate",
      "node_path": "Metastatic Breast Cancer Treatment Decision (ESMO 2021/24) -> Initial Biopsy, Biomarker & Staging Assessment (updated) -> Breast Cancer Subtype Classification -> Luminal Breast Cancer (ER+/HER2\u00e2\u20ac\u2018) -> Additional Biomarker Testing for Luminal BC (updated) -> Second\u00e2\u20ac\u2018line After CDK4/6 Progression (enhanced) -> PIK3CA wild\u00e2\u20ac\u2018type & BRCA/PALB2 wild\u00e2\u20ac\u2018type",
      "rationale": "Patient has Luminal metastatic breast cancer. Recommended after progression on 1 prior line(s).",
      "keywords": [
        "mTOR inhibitor",
        "aromatase inhibitor",
        "everolimus",
        "systemic therapy",
        "metastatic breast cancer",
        "exemestane",
        "combination therapy"
      ]
    }
  ],
  "total_recommendations": 2
}